Literature DB >> 19755794

MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs.

Yutaka Kawahigashi1, Takuya Mishima, Yoshiaki Mizuguchi, Yasuo Arima, Shigeki Yokomuro, Tomohiro Kanda, Osamu Ishibashi, Hiroshi Yoshida, Takashi Tajiri, Toshihiro Takizawa.   

Abstract

Intrahepatic cholangiocarcinoma (ICC), which arises in the small bile ducts of the liver, is the second most common liver malignancy. Although modulation of microRNA (miRNA) expression has been shown to be a potent sign of malignant tumors, miRNA profiles of ICC remains unclear. We performed sequencing analysis of the small RNA libraries of 2 ICC cell lines (HuCCT1 and MEC) and one normal intrahepatic biliary epithelial cell line (HIBEpiC) to produce the miRNA profiles of ICC in vitro. Furthermore, by means of the real-time polymerase chain reaction (PCR) we validated the differential expression of miRNAs cloned exclusively or predominantly from each of the cell lines. A total of 35,759 small RNA clones were obtained from the 3 cell lines. We identified 27 miRNAs that were expressed exclusively or predominantly in each cell line. Subsequent validation with the real-time PCR confirmed that the miRNAs hsa-miR-22, -125a, -127, -199a, -199a*, -214, -376a, and -424 were expressed specifically in HIBEpiC but were downregulated in the ICC cell lines. Our study provides important information for facilitating studies of the functional role(s) of miRNAs in carcinogenesis of the hepatobiliary system. The biliary epithelial cell-specific miRNAs identified in this study may serve as potential biomarkers for ICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19755794     DOI: 10.1272/jnms.76.188

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  34 in total

1.  miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.

Authors:  Nataliya Razumilava; Steve F Bronk; Rory L Smoot; Christian D Fingas; Nathan W Werneburg; Lewis R Roberts; Justin L Mott
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

Review 2.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

Review 3.  MicroRNA regulation of innate immune responses in epithelial cells.

Authors:  Rui Zhou; Steven P O'Hara; Xian-Ming Chen
Journal:  Cell Mol Immunol       Date:  2011-07-04       Impact factor: 11.530

Review 4.  MicroRNAs and benign biliary tract diseases.

Authors:  Sergio A Gradilone; Steven P O'Hara; Tetyana V Masyuk; Maria Jose Lorenzo Pisarello; Nicholas F LaRusso
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

Review 5.  The role of miRNAs in cholangiocarcinoma.

Authors:  Jessica A Howell; Shahid A Khan
Journal:  Hepat Oncol       Date:  2016-03-29

6.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

Review 7.  Genetic profiling of intrahepatic cholangiocarcinoma.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

Review 8.  Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.

Authors:  Hiroaki Haga; Irene Yan; Kenji Takahashi; Joseph Wood; Tushar Patel
Journal:  Gene Expr       Date:  2014

Review 9.  OxymiRs in cutaneous development, wound repair and regeneration.

Authors:  Chandan K Sen; Sashwati Roy
Journal:  Semin Cell Dev Biol       Date:  2012-10-10       Impact factor: 7.727

10.  microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity.

Authors:  J Zhang; Y Yang; T Yang; Y Liu; A Li; S Fu; M Wu; Z Pan; W Zhou
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.